Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 211

1.

Role of Donor Clonal Hematopoiesis in Allogeneic Hematopoietic Stem-Cell Transplantation.

Frick M, Chan W, Arends CM, Hablesreiter R, Halik A, Heuser M, Michonneau D, Blau O, Hoyer K, Christen F, Galan-Sousa J, Noerenberg D, Wais V, Stadler M, Yoshida K, Schetelig J, Schuler E, Thol F, Clappier E, Christopeit M, Ayuk F, Bornhäuser M, Blau IW, Ogawa S, Zemojtel T, Gerbitz A, Wagner EM, Spriewald BM, Schrezenmeier H, Kuchenbauer F, Kobbe G, Wiesneth M, Koldehoff M, Socié G, Kroeger N, Bullinger L, Thiede C, Damm F.

J Clin Oncol. 2018 Nov 7:JCO2018792184. doi: 10.1200/JCO.2018.79.2184. [Epub ahead of print]

PMID:
30403573
2.

Jak2V617F and Dnmt3a loss cooperate to induce myelofibrosis through activated enhancer-driven inflammation.

Jacquelin S, Straube J, Cooper L, Vu T, Song A, Bywater M, Baxter E, Heidecker M, Wackrow B, Porter A, Ling V, Green J, Austin R, Kazakoff S, Waddell N, Hesson LB, Pimanda JE, Stegelmann F, Bullinger L, Döhner K, Rampal RK, Heckl D, Hill GR, Lane SW.

Blood. 2018 Oct 26. pii: blood-2018-04-846220. doi: 10.1182/blood-2018-04-846220. [Epub ahead of print]

PMID:
30366920
3.

Nuclear FOXO1 promotes lymphomagenesis in germinal center B cells.

Kabrani E, Chu VT, Tasouri E, Sommermann T, Baßler K, Ulas T, Zenz T, Bullinger L, Schultze J, Rajewsky K, Sander S.

Blood. 2018 Oct 17. pii: blood-2018-06-856203. doi: 10.1182/blood-2018-06-856203. [Epub ahead of print]

PMID:
30333121
4.

Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care.

Döhner H, Dolnik A, Tang L, Seymour JF, Minden MD, Stone RM, Del Castillo TB, Al-Ali HK, Santini V, Vyas P, Beach CL, MacBeth KJ, Skikne BS, Songer S, Tu N, Bullinger L, Dombret H.

Leukemia. 2018 Oct 1. doi: 10.1038/s41375-018-0257-z. [Epub ahead of print]

PMID:
30275526
5.

Circular RNAs in Cancer.

Lux S, Bullinger L.

Adv Exp Med Biol. 2018;1087:215-230. doi: 10.1007/978-981-13-1426-1_17.

PMID:
30259369
6.

The Affordable Care Act, Breastfeeding, and Breast Pump Health Insurance Coverage.

Kapinos KA, Bullinger L, Gurley-Calvez T.

JAMA Pediatr. 2018 Nov 1;172(11):1002-1004. doi: 10.1001/jamapediatrics.2018.2003. No abstract available.

PMID:
30208472
7.

Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML.

Thol F, Gabdoulline R, Liebich A, Klement P, Schiller J, Kandziora C, Hambach L, Stadler M, Koenecke C, Flintrop M, Pankratz M, Wichmann M, Neziri B, Büttner K, Heida B, Klesse S, Chaturvedi A, Kloos A, Göhring G, Schlegelberger B, Gaidzik VI, Bullinger L, Fiedler W, Heim A, Hamwi I, Eder M, Krauter J, Schlenk RF, Paschka P, Döhner K, Döhner H, Ganser A, Heuser M.

Blood. 2018 Oct 18;132(16):1703-1713. doi: 10.1182/blood-2018-02-829911. Epub 2018 Sep 6.

PMID:
30190321
8.

Author Correction: BCAT1 restricts αKG levels in AML stem cells leading to IDHmut-like DNA hypermethylation.

Raffel S, Falcone M, Kneisel N, Hansson J, Wang W, Lutz C, Bullinger L, Poschet G, Nonnenmacher Y, Barnert A, Bahr C, Zeisberger P, Przybylla A, Sohn M, Tönjes M, Erez A, Adler L, Jensen P, Scholl C, Fröhling S, Cocciardi S, Wuchter P, Thiede C, Flörcken A, Westermann J, Ehninger G, Lichter P, Hiller K, Hell R, Herrmann C, Ho AD, Krijgsveld J, Radlwimmer B, Trumpp A.

Nature. 2018 Aug;560(7718):E28. doi: 10.1038/s41586-018-0403-9.

PMID:
30069041
9.

Correction: MYC-containing amplicons in acute myeloid leukemia: genomic structures, evolution, and transcriptional consequences.

L'Abbate A, Tolomeo D, Cifola I, Severgnini M, Turchiano A, Augello B, Squeo G, D'Addabbo P, Traversa D, Daniele G, Lonoce A, Pafundi M, Carella M, Palumbo O, Dolnik A, Muehlematter D, Schoumans J, Van Roy N, De Bellis G, Martinelli G, Merla G, Bullinger L, Haferlach C, Storlazzi CT.

Leukemia. 2018 Oct;32(10):2304. doi: 10.1038/s41375-018-0177-y.

PMID:
29985446
10.

MYB induces the expression of the oncogenic corepressor SKI in acute myeloid leukemia.

Frech M, Teichler S, Feld C, Bouchard C, Berberich H, Sorg K, Mernberger M, Bullinger L, Bauer UM, Neubauer A.

Oncotarget. 2018 Apr 27;9(32):22423-22435. doi: 10.18632/oncotarget.25051. eCollection 2018 Apr 27.

11.

Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors.

Maifrede S, Nieborowska-Skorska M, Sullivan-Reed K, Dasgupta Y, Podszywalow-Bartnicka P, Le BV, Solecka M, Lian Z, Belyaeva EA, Nersesyan A, Machnicki MM, Toma M, Chatain N, Rydzanicz M, Zhao H, Jelinek J, Piwocka K, Sliwinski T, Stoklosa T, Ploski R, Fischer T, Sykes SM, Koschmieder S, Bullinger L, Valent P, Wasik MA, Huang J, Skorski T.

Blood. 2018 Jul 5;132(1):67-77. doi: 10.1182/blood-2018-02-834895. Epub 2018 May 21.

PMID:
29784639
12.

UTX-mediated enhancer and chromatin remodeling suppresses myeloid leukemogenesis through noncatalytic inverse regulation of ETS and GATA programs.

Gozdecka M, Meduri E, Mazan M, Tzelepis K, Dudek M, Knights AJ, Pardo M, Yu L, Choudhary JS, Metzakopian E, Iyer V, Yun H, Park N, Varela I, Bautista R, Collord G, Dovey O, Garyfallos DA, De Braekeleer E, Kondo S, Cooper J, Göttgens B, Bullinger L, Northcott PA, Adams D, Vassiliou GS, Huntly BJP.

Nat Genet. 2018 Jun;50(6):883-894. doi: 10.1038/s41588-018-0114-z. Epub 2018 May 7.

PMID:
29736013
13.

Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia-results of the AMLSG 11-08 trial.

Paschka P, Schlenk RF, Weber D, Benner A, Bullinger L, Heuser M, Gaidzik VI, Thol F, Agrawal M, Teleanu V, Lübbert M, Fiedler W, Radsak M, Krauter J, Horst HA, Greil R, Mayer K, Kündgen A, Martens U, Heil G, Salih HR, Hertenstein B, Schwänen C, Wulf G, Lange E, Pfreundschuh M, Ringhoffer M, Girschikofsky M, Heinicke T, Kraemer D, Göhring G, Ganser A, Döhner K, Döhner H.

Leukemia. 2018 Jul;32(7):1621-1630. doi: 10.1038/s41375-018-0129-6. Epub 2018 Apr 17.

PMID:
29720733
14.

RET-mediated autophagy suppression as targetable co-dependence in acute myeloid leukemia.

Rudat S, Pfaus A, Cheng YY, Holtmann J, Ellegast JM, Bühler C, Marcantonio DD, Martinez E, Göllner S, Wickenhauser C, Müller-Tidow C, Lutz C, Bullinger L, Milsom MD, Sykes SM, Fröhling S, Scholl C.

Leukemia. 2018 Oct;32(10):2189-2202. doi: 10.1038/s41375-018-0102-4. Epub 2018 Mar 22.

PMID:
29654265
15.

Epigenetic therapy: azacytidine and decitabine in acute myeloid leukemia.

Bohl SR, Bullinger L, Rücker FG.

Expert Rev Hematol. 2018 May;11(5):361-371. doi: 10.1080/17474086.2018.1453802. Epub 2018 Mar 27.

PMID:
29543073
16.

FACS single cell index sorting is highly reliable and determines immune phenotypes of clonally expanded T cells.

Penter L, Dietze K, Bullinger L, Westermann J, Rahn HP, Hansmann L.

Eur J Immunol. 2018 Jul;48(7):1248-1250. doi: 10.1002/eji.201847507. Epub 2018 Apr 3.

PMID:
29537492
17.

Hematopoietic lineage distribution and evolutionary dynamics of clonal hematopoiesis.

Arends CM, Galan-Sousa J, Hoyer K, Chan W, Jäger M, Yoshida K, Seemann R, Noerenberg D, Waldhueter N, Fleischer-Notter H, Christen F, Schmitt CA, Dörken B, Pelzer U, Sinn M, Zemojtel T, Ogawa S, Märdian S, Schreiber A, Kunitz A, Krüger U, Bullinger L, Mylonas E, Frick M, Damm F.

Leukemia. 2018 Sep;32(9):1908-1919. doi: 10.1038/s41375-018-0047-7. Epub 2018 Mar 1.

PMID:
29491455
18.

MYC-containing amplicons in acute myeloid leukemia: genomic structures, evolution, and transcriptional consequences.

L Abbate A, Tolomeo D, Cifola I, Severgnini M, Turchiano A, Augello B, Squeo G, D Addabbo P, Traversa D, Daniele G, Lonoce A, Pafundi M, Carella M, Palumbo O, Dolnik A, Muehlematter D, Schoumans J, Van Roy N, De Bellis G, Martinelli G, Merla G, Bullinger L, Haferlach C, Storlazzi CT.

Leukemia. 2018 Oct;32(10):2152-2166. doi: 10.1038/s41375-018-0033-0. Epub 2018 Feb 22. Erratum in: Leukemia. 2018 Jul 9;:.

19.

The cell fate determinant Scribble is required for maintenance of hematopoietic stem cell function.

Mohr J, Dash BP, Schnoeder TM, Wolleschak D, Herzog C, Tubio Santamaria N, Weinert S, Godavarthy S, Zanetti C, Naumann M, Hartleben B, Huber TB, Krause DS, Kähne T, Bullinger L, Heidel FH.

Leukemia. 2018 May;32(5):1211-1221. doi: 10.1038/s41375-018-0025-0. Epub 2018 Jan 30.

PMID:
29467485
20.

Bevacizumab in temozolomide refractory high-grade gliomas: single-centre experience and review of the literature.

Jeck J, Kassubek R, Coburger J, Edenhofer S, Schönsteiner SS, Ludolph AC, Schmitz B, Engelke J, Mayer-Steinacker R, Lewerenz J, Bullinger L.

Ther Adv Neurol Disord. 2018 Jan 21;11:1756285617753597. doi: 10.1177/1756285617753597. eCollection 2018.

21.

Effect of the Affordable Care Act on Breastfeeding Outcomes.

Gurley-Calvez T, Bullinger L, Kapinos KA.

Am J Public Health. 2018 Feb;108(2):277-283. doi: 10.2105/AJPH.2017.304108. Epub 2017 Dec 21.

PMID:
29267066
22.

Expression of CD274 (PD-L1) is associated with unfavourable recurrent mutations in AML.

Zajac M, Zaleska J, Dolnik A, Bullinger L, Giannopoulos K.

Br J Haematol. 2017 Dec 19. doi: 10.1111/bjh.15040. [Epub ahead of print] No abstract available.

PMID:
29265177
23.

Analysis of NPM1 splice variants reveals differential expression patterns of prognostic value in acute myeloid leukemia.

Zajac M, Dolnik A, Stasiak G, Zaleska J, Kielbus M, Czapinski J, Schunn M, Correa SC, Glodkowska-Mrowka E, Sundaram RC, Jankowska-Lecka O, Schlenk RF, Döhner H, Döhner K, Stepulak A, Bullinger L, Giannopoulos K.

Oncotarget. 2017 Aug 3;8(56):95163-95175. doi: 10.18632/oncotarget.19871. eCollection 2017 Nov 10.

24.

Protein phosphatase 4 regulatory subunit 2 (PPP4R2) is recurrently deleted in acute myeloid leukemia and required for efficient DNA double strand break repair.

Herzig JK, Bullinger L, Tasdogan A, Zimmermann P, Schlegel M, Teleanu V, Weber D, Rücker FG, Paschka P, Dolnik A, Schneider E, Kuchenbauer F, Heidel FH, Buske C, Döhner H, Döhner K, Gaidzik VI.

Oncotarget. 2017 Sep 21;8(56):95038-95053. doi: 10.18632/oncotarget.21119. eCollection 2017 Nov 10.

25.

Micro-ribonucleic acid-155 is a direct target of Meis1, but not a driver in acute myeloid leukemia.

Schneider E, Staffas A, Röhner L, Malmberg ED, Ashouri A, Krowiorz K, Pochert N, Miller C, Wei SY, Arabanian L, Buske C, Döhner H, Bullinger L, Fogelstrand L, Heuser M, Döhner K, Xiang P, Ruschmann J, Petriv OI, Heravi-Moussavi A, Hansen CL, Hirst M, Humphries RK, Rouhi A, Palmqvist L, Kuchenbauer F.

Haematologica. 2018 Feb;103(2):246-255. doi: 10.3324/haematol.2017.177485. Epub 2017 Dec 7.

26.

MYC-containing amplicons in acute myeloid leukemia: Genomic structures, evolution, and transcriptional consequences.

ĹAbbate A, Tolomeo D, Cifola I, Severgnini M, Turchiano A, Augello B, Squeo G, D Addabbo P, Traversa D, Daniele G, Lonoce A, Pafundi M, Carella M, Palumbo O, Dolnik A, Muehlematter D, Schoumans J, Van Roy N, De Bellis G, Martinelli G, Merla G, Bullinger L, Haferlach C, Storlazzi CT.

Leukemia. 2017 Nov 28. doi: 10.1038/leu.2017.337. [Epub ahead of print]

PMID:
29180669
27.

BCAT1 restricts αKG levels in AML stem cells leading to IDHmut-like DNA hypermethylation.

Raffel S, Falcone M, Kneisel N, Hansson J, Wang W, Lutz C, Bullinger L, Poschet G, Nonnenmacher Y, Barnert A, Bahr C, Zeisberger P, Przybylla A, Sohn M, Tönjes M, Erez A, Adler L, Jensen P, Scholl C, Fröhling S, Cocciardi S, Wuchter P, Thiede C, Flörcken A, Westermann J, Ehninger G, Lichter P, Hiller K, Hell R, Herrmann C, Ho AD, Krijgsveld J, Radlwimmer B, Trumpp A.

Nature. 2017 Nov 16;551(7680):384-388. doi: 10.1038/nature24294. Epub 2017 Nov 8. Erratum in: Nature. 2018 Aug;560(7718):E28.

PMID:
29144447
28.

Reduced-toxicity conditioning for allogeneic hematopoietic cell transplantation in elderly or comorbid patients with AML using fludarabine, BCNU and melphalan: disease stage at transplant determines outcome.

Wais V, Kündgen L, Bohl SR, von Harsdorf S, Schlenk RF, Döhner K, Teleanu V, Bullinger L, Nguyen TM, Drognitz K, Moulin JC, Binnenhei M, Bentz M, Döhner H, Bunjes D, Kuchenbauer F, Ringhoffer M.

Bone Marrow Transplant. 2018 Jan;53(1):94-96. doi: 10.1038/bmt.2017.211. Epub 2017 Nov 13. No abstract available.

PMID:
29131153
29.

Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO).

Nagel G, Weber D, Fromm E, Erhardt S, Lübbert M, Fiedler W, Kindler T, Krauter J, Brossart P, Kündgen A, Salih HR, Westermann J, Wulf G, Hertenstein B, Wattad M, Götze K, Kraemer D, Heinicke T, Girschikofsky M, Derigs HG, Horst HA, Rudolph C, Heuser M, Göhring G, Teleanu V, Bullinger L, Thol F, Gaidzik VI, Paschka P, Döhner K, Ganser A, Döhner H, Schlenk RF; German-Austrian AML Study Group (AMLSG).

Ann Hematol. 2017 Dec;96(12):1993-2003. doi: 10.1007/s00277-017-3150-3. Epub 2017 Oct 31.

30.

Chromothripsis is linked to TP53 alteration, cell cycle impairment, and dismal outcome in acute myeloid leukemia with complex karyotype.

Rücker FG, Dolnik A, Blätte TJ, Teleanu V, Ernst A, Thol F, Heuser M, Ganser A, Döhner H, Döhner K, Bullinger L.

Haematologica. 2018 Jan;103(1):e17-e20. doi: 10.3324/haematol.2017.180497. Epub 2017 Oct 27. No abstract available.

31.

Circular RNAs of the nucleophosmin (NPM1) gene in acute myeloid leukemia.

Hirsch S, Blätte TJ, Grasedieck S, Cocciardi S, Rouhi A, Jongen-Lavrencic M, Paschka P, Krönke J, Gaidzik VI, Döhner H, Schlenk RF, Kuchenbauer F, Döhner K, Dolnik A, Bullinger L.

Haematologica. 2017 Dec;102(12):2039-2047. doi: 10.3324/haematol.2017.172866. Epub 2017 Sep 29.

32.

Acute myeloid leukemia with mutated nucleophosmin 1: an immunogenic acute myeloid leukemia subtype and potential candidate for immune checkpoint inhibition.

Greiner J, Hofmann S, Schmitt M, Götz M, Wiesneth M, Schrezenmeier H, Bunjes D, Döhner H, Bullinger L.

Haematologica. 2017 Dec;102(12):e499-e501. doi: 10.3324/haematol.2017.176461. Epub 2017 Sep 21. No abstract available.

33.

The oligodendrocyte lineage transcription factor 2 (OLIG2) is epigenetically regulated in acute myeloid leukemia.

Yalcin A, Kovarbasic M, Wehrle J, Claus R, Becker H, Abdelkarim M, Gaidzik VI, Schmidts A, Wäsch R, Pahl HL, Döhner K, Bullinger L, Duyster J, Lübbert M, Hackanson B.

Exp Hematol. 2017 Nov;55:76-85.e3. doi: 10.1016/j.exphem.2017.07.009. Epub 2017 Jul 28.

PMID:
28760688
34.

Partitioned learning of deep Boltzmann machines for SNP data.

Hess M, Lenz S, Blätte TJ, Bullinger L, Binder H.

Bioinformatics. 2017 Oct 15;33(20):3173-3180. doi: 10.1093/bioinformatics/btx408.

PMID:
28655145
35.

DNMT3A mutant transcript levels persist in remission and do not predict outcome in patients with acute myeloid leukemia.

Gaidzik VI, Weber D, Paschka P, Kaumanns A, Krieger S, Corbacioglu A, Krönke J, Kapp-Schwoerer S, Krämer D, Horst HA, Schmidt-Wolf I, Held G, Kündgen A, Ringhoffer M, Götze K, Kindler T, Fiedler W, Wattad M, Schlenk RF, Bullinger L, Teleanu V, Schlegelberger B, Thol F, Heuser M, Ganser A, Döhner H, Döhner K; German-Austrian Acute Myeloid Leukemia Study Group (AMLSG).

Leukemia. 2018 Jan;32(1):30-37. doi: 10.1038/leu.2017.200. Epub 2017 Jun 23.

PMID:
28643785
36.

Novel Treatment Options in Head and Neck Cancer.

Schuler PJ, Laban S, Doescher J, Bullinger L, Hoffmann TK.

Oncol Res Treat. 2017;40(6):342-346. doi: 10.1159/000477254. Epub 2017 May 17. Review.

37.

Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cells.

Nieborowska-Skorska M, Sullivan K, Dasgupta Y, Podszywalow-Bartnicka P, Hoser G, Maifrede S, Martinez E, Di Marcantonio D, Bolton-Gillespie E, Cramer-Morales K, Lee J, Li M, Slupianek A, Gritsyuk D, Cerny-Reiterer S, Seferynska I, Stoklosa T, Bullinger L, Zhao H, Gorbunova V, Piwocka K, Valent P, Civin CI, Muschen M, Dick JE, Wang JC, Bhatia S, Bhatia R, Eppert K, Minden MD, Sykes SM, Skorski T.

J Clin Invest. 2017 Jun 1;127(6):2392-2406. doi: 10.1172/JCI90825. Epub 2017 May 8.

38.

Heterodimerization of AML1/ETO with CBFβ is required for leukemogenesis but not for myeloproliferation.

Thiel VN, Giaimo BD, Schwarz P, Soller K, Vas V, Bartkuhn M, Blätte TJ, Döhner K, Bullinger L, Borggrefe T, Geiger H, Oswald F.

Leukemia. 2017 Nov;31(11):2491-2502. doi: 10.1038/leu.2017.105. Epub 2017 Mar 31.

39.

Genomics of Acute Myeloid Leukemia Diagnosis and Pathways.

Bullinger L, Döhner K, Döhner H.

J Clin Oncol. 2017 Mar 20;35(9):934-946. doi: 10.1200/JCO.2016.71.2208. Epub 2017 Feb 13. Review.

PMID:
28297624
40.

Therapy for Recurrent High-Grade Gliomas: Results of a Prospective Multicenter Study on Health-Related Quality of Life.

Stöckelmaier L, Renovanz M, König J, Nickel K, Hickmann AK, Mayer-Steinacker R, Nadji-Ohl M, Ganslandt O, Bullinger L, Wirtz CR, Coburger J.

World Neurosurg. 2017 Jun;102:383-399. doi: 10.1016/j.wneu.2017.02.061. Epub 2017 Mar 11.

PMID:
28288921
41.

Gene expression analysis of decitabine treated AML: high impact of tumor suppressor gene expression changes.

Bohl SR, Dolnik A, Jensen T, Lang KM, Hackanson B, Gaidzik VI, Paschka P, Knudsen S, Döhner K, Döhner H, Claus R, Lübbert M, Bullinger L.

Leuk Lymphoma. 2017 Sep;58(9):1-4. doi: 10.1080/10428194.2017.1287360. Epub 2017 Feb 13. No abstract available.

PMID:
28278722
42.

The patients' view: impact of the extent of resection, intraoperative imaging, and awake surgery on health-related quality of life in high-grade glioma patients-results of a multicenter cross-sectional study.

Nickel K, Renovanz M, König J, Stöckelmaier L, Hickmann AK, Nadji-Ohl M, Engelke J, Weimann E, Freudenstein D, Ganslandt O, Bullinger L, Wirtz CR, Coburger J.

Neurosurg Rev. 2018 Jan;41(1):207-219. doi: 10.1007/s10143-017-0836-x. Epub 2017 Mar 6.

PMID:
28265818
43.

Identifying ischemic stroke associated with cancer: a multiple model derived from a case-control analysis.

Kassubek R, Bullinger L, Kassubek J, Dreyhaupt J, Ludolph AC, Althaus K, Lewerenz J.

J Neurol. 2017 Apr;264(4):781-791. doi: 10.1007/s00415-017-8432-0. Epub 2017 Feb 28.

PMID:
28247043
44.

Response Evaluation in Head and Neck Oncology: Definition and Prediction.

Hoffmann TK, Schuler PJ, Laban S, Grässlin R, Beer M, Beer AJ, Friebe-Hoffmann U, Bullinger L, Möller P, Wiegel T.

ORL J Otorhinolaryngol Relat Spec. 2017;79(1-2):14-23. doi: 10.1159/000455726. Epub 2017 Feb 24. Review.

PMID:
28231577
45.

The Effect of Minimum Wages on Adolescent Fertility: A Nationwide Analysis.

Bullinger LR.

Am J Public Health. 2017 Mar;107(3):447-452. doi: 10.2105/AJPH.2016.303604. Epub 2017 Jan 19.

PMID:
28103069
46.

Precision oncology for acute myeloid leukemia using a knowledge bank approach.

Gerstung M, Papaemmanuil E, Martincorena I, Bullinger L, Gaidzik VI, Paschka P, Heuser M, Thol F, Bolli N, Ganly P, Ganser A, McDermott U, Döhner K, Schlenk RF, Döhner H, Campbell PJ.

Nat Genet. 2017 Mar;49(3):332-340. doi: 10.1038/ng.3756. Epub 2017 Jan 16.

47.

Incidence and prognostic impact of ASXL2 mutations in adult acute myeloid leukemia patients with t(8;21)(q22;q22): a study of the German-Austrian AML Study Group.

Jahn N, Agrawal M, Bullinger L, Weber D, Corbacioglu A, Gaidzik VI, Schmalbrock L, Thol F, Heuser M, Krauter J, Göhring G, Kündgen A, Fiedler W, Wattad M, Held G, Köhne CH, Horst HA, Lübbert M, Ganser A, Schlenk RF, Döhner H, Döhner K, Paschka P.

Leukemia. 2017 Apr;31(4):1012-1015. doi: 10.1038/leu.2017.18. Epub 2017 Jan 16. No abstract available.

PMID:
28090090
48.

Evaluating the impact of genetic and epigenetic aberrations on survival and response in acute myeloid leukemia patients receiving epigenetic therapy.

Hiller JK, Schmoor C, Gaidzik VI, Schmidt-Salzmann C, Yalcin A, Abdelkarim M, Blagitko-Dorfs N, Döhner K, Bullinger L, Duyster J, Lübbert M, Hackanson B.

Ann Hematol. 2017 Apr;96(4):559-565. doi: 10.1007/s00277-016-2912-7. Epub 2017 Jan 5.

PMID:
28058491
49.

Prospective identification of resistance mechanisms to HSP90 inhibition in KRAS mutant cancer cells.

Rouhi A, Miller C, Grasedieck S, Reinhart S, Stolze B, Döhner H, Kuchenbauer F, Bullinger L, Fröhling S, Scholl C.

Oncotarget. 2017 Jan 31;8(5):7678-7690. doi: 10.18632/oncotarget.13841.

50.

IKZF1 expression is a prognostic marker in newly diagnosed standard-risk multiple myeloma treated with lenalidomide and intensive chemotherapy: a study of the German Myeloma Study Group (DSMM).

Krönke J, Kuchenbauer F, Kull M, Teleanu V, Bullinger L, Bunjes D, Greiner A, Kolmus S, Köpff S, Schreder M, Mügge LO, Straka C, Engelhardt M, Döhner H, Einsele H, Bassermann F, Bargou R, Knop S, Langer C.

Leukemia. 2017 Jun;31(6):1363-1367. doi: 10.1038/leu.2016.384. Epub 2016 Dec 26.

PMID:
28017969

Supplemental Content

Loading ...
Support Center